YOLFTbeta
Definium Therapeutics, Inc.

Definium Therapeutics, Inc.

DFTX · NASDAQ · Healthcare / Biotechnology

32.08USD-0.92 (-2.79%)

Price History

Full chart

Market Stats

Previous Close33.00
Open32.70
Day Range31.47 – 32.70
52-Week Range10.47 – 49.70
Volume777.30K
Market Cap4.88B
P/E (TTM)0.00
Forward P/E0.00
EPS-3.43
Dividend Yield0.00%
Beta2.19
50-Day Avg37.77
200-Day Avg29.60

About

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Robert Barrow
  • Employees105
  • HeadquartersOne World Trade Center, New York, NY, United States, 10007, USA
  • Websitehttps://definiumtx.com

Leadership

  • Mr. Robert BarrowCEO & Director · b. 1989
  • Ms. Brandi L. Roberts CPA, M.B.A.Chief Financial Officer · b. 1974
  • Dr. Daniel Rollings Karlin M.A., M.D.Chief Medical Officer · b. 1980
  • Dr. Scott M. Freeman M.D.Co-Founder & Clinical Advisor · b. 1957
  • Mr. Leonard LatchmanCo-Founder
  • Mr. Peter MackSenior Vice President of Pharmaceutical Development & Operations
  • Ms. Gitanjali Jain OgawaVP & Head of Investor Relations
  • Mr. Mark R. Sullivan J.D.Chief Legal Officer & Corporate Secretary · b. 1971
  • Ms. Beth CalitriVice President of Corporate Communications
  • Ms. Stephanie Fagan M.S.Chief Corporate Affairs Officer

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue------00000
Cost of Revenue--5.50K6.68K6.68K---3.16M527.00K-
Gross Profit---5.50K-6.68K-6.68K----3.16M-527.00K-
Operating Expense--1.23M855.26K461.50K---90.70M103.39M-
Operating Income-94.55K-111.25K-1.24M-861.94K-468.18K-33.03M-93.85M-66.33M-93.87M-103.92M-166.31M
EBITDA-92.66K-111.25K-1.51M-851.26K-1.11M-33.22M-91.22M-52.12M-92.57M-105.87M-178.31M
Net Income-92.66K-179.90K-1.23M-857.94K-1.12M-34.10M-93.04M-56.80M-95.73M-108.68M-183.79M
R&D-----18.63M34.79M36.17M48.96M65.30M117.67M
Interest Expense-----164.00K359.00K1.50M920.00K2.28M5.48M

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets291.66K202.75K4.03M3.53M2.94M81.52M164.00M169.99M124.54M302.15M440.10M
Total Liabilities7.49K75.47K80.44K8.23K198.96K5.65M12.34M19.08M46.41M60.70M107.77M
Total Equity284.17K127.28K3.95M3.52M2.74M75.87M151.66M150.92M78.13M241.45M332.33M
Cash4.62K10.96K3.98K154.79K17.93K80.09M133.54M142.14M99.70M273.74M257.84M
Total Debt--15.74K----72.00K14.13M21.85M-
Net Debt-4.62K-10.96K11.77K-154.79K-17.93K-80.09M-133.54M-142.07M-85.58M-251.89M-257.84M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-46.56K-26.64K-665.98K-722.45K-208.12K-23.60M-45.82M-50.14M-64.36M-79.13M-131.56M
Investing Cash Flow41.86K32.83K-3.67M541.34K-213.15K--297.00K----151.61M
Financing Cash Flow--330.914.35M312.05K288.36K96.70M98.82M59.05M21.85M253.20M267.27M
Capital Expenditure030.10K2.15M1.04M313.46K000000
Free Cash Flow-46.56K-56.73K-2.82M-1.77M-521.58K-23.60M-45.82M-50.14M-64.36M-79.13M-131.56M
FCF to OCF100.00%213.00%422.77%244.49%250.61%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateNov 30, 2016Feb 28, 2017May 31, 2017Aug 31, 2017Nov 30, 2017Feb 28, 2018May 31, 2018Aug 31, 2018Nov 30, 2018Feb 28, 2019May 31, 2019Aug 31, 2019May 19, 2020Aug 14, 2020Nov 12, 2020Apr 6, 2021Aug 12, 2021Nov 12, 2021Mar 28, 2022May 16, 2022Aug 11, 2022Nov 10, 2022Mar 9, 2023May 4, 2023Aug 3, 2023Nov 2, 2023Feb 28, 2024May 8, 2024Aug 13, 2024Nov 7, 2024Mar 6, 2025May 8, 2025Jul 31, 2025Nov 6, 2025Feb 26, 2026May 7, 2026Aug 6, 2026Nov 5, 2026Nov 9, 2026
EPS Estimate--------------0.30-0.45-0.30-0.60-0.55-0.60-0.70-0.75-0.63-0.13-0.44-0.53-0.67-0.46-0.56-0.33-0.26-0.31-0.37-0.36-0.50-0.45-0.49-0.55-0.54-0.55
EPS Actual-2.05-1.35-1.75-1.67-0.53-0.78-1.51-0.62-0.36-0.47-0.41-1.62-0.53-0.02-0.45-0.04-1.35-0.90-0.04-0.60-0.60-0.56-0.13-0.65-0.76-0.45-2.44-1.14-0.29-0.18-0.41-0.35-0.50-0.78-0.45-0.71-1.44--
Surprise-------------93.33%0.00%86.67%-125.00%-63.64%93.33%14.29%20.00%11.11%0.00%-47.73%-43.40%32.84%-427.11%-103.57%12.12%30.77%-32.26%5.41%-38.89%-56.00%0.00%-44.90%-161.82%--
Timing--------------After-hours-After-hoursPre-market-Pre-marketAfter-hoursPre-market-After-hoursAfter-hoursAfter-hours-After-hoursPre-marketAfter-hours-Pre-marketAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap4.88B
Enterprise Value3.83B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book5.31
EPS-3.43
Book Value6.84
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-166.28M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-64.09%
Return on Assets-20.64%
Shares Outstanding134.37M
Shares Float125.52M
Beta2.19
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 19 analystsTarget 72.56
  • Strong Buy
    14
  • Buy
    5

Ownership Breakdown

Institutions
96.39%
Insiders
2.57%
Retail / Other
1.04%

Top Institutional Holders

  • BlackRock Inc
    11.23M8.36%
  • venBio Select Advisor LLC
    7.19M5.35%
  • Driehaus Capital Management LLC
    6.85M5.09%
  • Jupiter Topco LLC
    5.62M4.18%
  • Capital World Investors
    5.37M3.99%
  • FMR Inc
    4.75M3.54%
  • T. Rowe Price Associates, Inc.
    4.65M3.46%
  • Geode Capital Management, LLC
    3.64M2.71%
  • State Street Corp
    3.07M2.28%
  • Capital Research & Mgmt Co - Division 3
    2.96M2.21%
  • Octagon Capital Advisors LP
    2.95M2.20%
  • Wellington Management Company LLP
    2.95M2.20%
  • Deep Track Capital, LP
    2.75M2.05%
  • COMMODORE CAPITAL LP
    2.00M1.49%
  • AllianceBernstein L.P.
    1.80M1.34%
  • The Goldman Sachs Group Inc
    1.80M1.34%
  • Citadel Advisors Llc
    1.69M1.26%
  • Vanguard Portfolio Management, LLC
    1.65M1.23%

Top Fund Holders

  • American Funds SMALLCAP World A
    10.25M7.63%
  • iShares Russell 2000 ETF
    3.17M2.36%

Stock Splits

  • Aug 29, 20221:15